Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease

Kandimalla R , Thirumala V , Reddy PH (2016) Is Alzheimer’s disease a type 3 diabetes? A critical appraisal. Biochim Biophys Acta. doi: 10.1016/j.bbadis.2016.08.018

Wang, 2016, Triad of risk for late onset Alzheimer’s: Mitochondrial haplotype, APOE genotype and chromosomal sex, Front Aging Neurosci, 8, 232, 10.3389/fnagi.2016.00232

Tramutola A , Lanzillotta C , Perluigi M , Butterfield DA (2016) Oxidative stress, protein modification and Alzheimer disease. Brain Res Bull. doi: 10.1016/j.brainresbull.2016.06.005

Selkoe, 2008, Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer’s disease, Handb Clin Neurol, 89, 245, 10.1016/S0072-9752(07)01223-7

LaFerla, 2007, Intracellular amyloid-beta in Alzheimer’s disease, Nat Rev Neurosci, 8, 499, 10.1038/nrn2168

Selkoe, 2008, Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior, Behav Brain Res, 192, 106, 10.1016/j.bbr.2008.02.016

Gyure, 2001, Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome, Arch Pathol Lab Med, 125, 489, 10.5858/2001-125-0489-IAAPDO

Oddo, 2003, Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction, Neuron, 39, 409, 10.1016/S0896-6273(03)00434-3

Knobloch, 2007, Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice, Neurobiol Aging, 28, 1297, 10.1016/j.neurobiolaging.2006.06.019

Xu, 1995, Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein, J Biol Chem, 270, 23243, 10.1074/jbc.270.40.23243

Kinoshita, 2003, Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes, J Cell Sci, 116, 3339, 10.1242/jcs.00643

Mizuguchi, 1992, Differential distribution of cellular forms of beta-amyloid precursor protein in murine glial cell cultures, Brain Res, 584, 219, 10.1016/0006-8993(92)90898-J

Omtri, 2012, Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: Ramifications for the Alzheimer’s drug discovery, Mol Pharm, 9, 1887, 10.1021/mp200530q

Cleary, 2005, Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function, Nat Neurosci, 8, 79, 10.1038/nn1372

Lai, 2010, Mechanisms of amyloid-beta peptide uptake by neurons: The role of lipid rafts and lipid raft-associated proteins, Int J Alzheimers Dis, 2011, 548380

Andreadis, 1992, Structure and novel exons of the human tau gene, Biochemistry, 31, 10626, 10.1021/bi00158a027

Miller, 2014, Tau phosphorylation and tau mislocalization mediate soluble Abeta oligomer-induced AMPA glutamate receptor signaling deficits, Eur J Neurosci, 39, 1214, 10.1111/ejn.12507

Selkoe, 2001, Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein, J Alzheimers Dis, 3, 75, 10.3233/JAD-2001-3111

Jack, 2013, Biomarker modeling of Alzheimer’s disease, Neuron, 80, 1347, 10.1016/j.neuron.2013.12.003

Crystal, 1988, Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer’s disease, Neurology, 38, 1682, 10.1212/WNL.38.11.1682

Iacono, 2014, Mild cognitive impairment and asymptomatic Alzheimer disease subjects: Equivalent beta-amyloid and tau loads with divergent cognitive outcomes, J Neuropathol Exp Neurol, 73, 295, 10.1097/NEN.0000000000000052

Sepulcre, 2016, In vivo tau, amyloid, and gray matter profiles in the aging brain, J Neurosci, 36, 7364, 10.1523/JNEUROSCI.0639-16.2016

Ossenkoppele, 2016, Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease, Brain, 139, 1551, 10.1093/brain/aww027

Wang, 2016, Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between beta-amyloid and tauopathy, JAMA Neurol, 73, 1070, 10.1001/jamaneurol.2016.2078

Jack, 2010, Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade, Lancet Neurol, 9, 119, 10.1016/S1474-4422(09)70299-6

Holtzman DM , Morris JC , Goate AM (2011) Alzheimer’s disease: The challenge of the second century. Sci Transl Med 3, 77sr71.

Bateman, 2012, Clinical and biomarker changes in dominantly inherited Alzheimer’s disease, N Engl J Med, 367, 795, 10.1056/NEJMoa1202753

Clark, 2012, Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study, Lancet Neurol, 11, 669, 10.1016/S1474-4422(12)70142-4

Herrup, 2015, The case for rejecting the amyloid cascade hypothesis, Nat Neurosci, 18, 794, 10.1038/nn.4017

Castello, 2014, Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease, BMC Neurol, 14, 169, 10.1186/s12883-014-0169-0

Castellani, 2011, Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’, J Pathol, 224, 147, 10.1002/path.2885

Swerdlow, 2014, The Alzheimer’s disease mitochondrial cascade hypothesis: Progress and perspectives, Biochim Biophys Acta, 1842, 1219, 10.1016/j.bbadis.2013.09.010

Beal, 1998, Mitochondrial dysfunction in neurodegenerative diseases, Biochim Biophys Acta, 1366, 211, 10.1016/S0005-2728(98)00114-5

Beal, 2005, Oxidative damage as an early marker of Alzheimer’s disease and mild cognitive impairment, Neurobiol Aging, 26, 585, 10.1016/j.neurobiolaging.2004.09.022

Atamna, 2007, Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease, Mitochondrion, 7, 297, 10.1016/j.mito.2007.06.001

Baloyannis, 2004, Mitochondrial alterations in Alzheimer’s disease, Am J Alzheimers Dis Other Demen, 19, 89, 10.1177/153331750401900205

Beal, 2005, Mitochondria take center stage in aging and neurodegeneration, Ann Neurol, 58, 495, 10.1002/ana.20624

Calkins, 2011, Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease, Hum Mol Genet, 20, 4515, 10.1093/hmg/ddr381

Cardoso, 2010, Mitochondrial control of autophagic lysosomal pathway in Alzheimer’s disease, Exp Neurol, 223, 294, 10.1016/j.expneurol.2009.06.008

Cardoso, 2004, Mitochondria dysfunction of Alzheimer’s disease cybrids enhances Abeta toxicity, J Neurochem, 89, 1417, 10.1111/j.1471-4159.2004.02438.x

Caspersen, 2005, Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease, FASEB J, 19, 2040, 10.1096/fj.05-3735fje

Du, 2010, Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model, Proc Natl Acad Sci U S A, 107, 18670, 10.1073/pnas.1006586107

Eckert, 2008, Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice, Neurodegener Dis, 5, 157, 10.1159/000113689

Leuner, 2012, Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation, Antioxid Redox Signal, 16, 1421, 10.1089/ars.2011.4173

Manczak, 2011, Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: Implications for neuronal damage, Hum Mol Genet, 20, 2495, 10.1093/hmg/ddr139

Trushina, 2007, Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases, Neuroscience, 145, 1233, 10.1016/j.neuroscience.2006.10.056

Trushina, 2012, Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer’s disease, PLoS One, 7, e32737, 10.1371/journal.pone.0032737

Zhu, 2013, Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease, J Alzheimers Dis, 33, S253

Kandimalla, 2016, Multiple faces of dynamin-related protein 1 and its role in Alzheimer’s disease pathogenesis, Biochim Biophys Acta, 1862, 814, 10.1016/j.bbadis.2015.12.018

Reiman, 2004, Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia, Proc Natl Acad Sci U S A, 101, 284, 10.1073/pnas.2635903100

Jagust, 2012, Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging, J Neurosci, 32, 18227, 10.1523/JNEUROSCI.3266-12.2012

Mosconi, 2008, Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease, Ann N Y Acad Sci, 1147, 180, 10.1196/annals.1427.007

Bubber, 2005, Mitochondrial abnormalities in Alzheimer brain: Mechanistic imlications, Ann Neurol, 57, 695, 10.1002/ana.20474

Blass, 2000, The mitochondrial spiral. An adequate cause of dementia in the Alzheimer’s syndrome, Ann N Y Acad Sci, 924, 170, 10.1111/j.1749-6632.2000.tb05576.x

Schmitt, 2012, Insights into mitochondrial dysfunction: Aging, amyloid-beta, and tau-A deleterious trio, Antioxid Redox Signal, 16, 1456, 10.1089/ars.2011.4400

Reddy, 2011, Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer’s disease, Brain Res, 1415, 136, 10.1016/j.brainres.2011.07.052

Sultana, 2011, Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer’s disease: Insights into the role of oxidative stress in Alzheimer’s disease and initial investigations into a potential biomarker for this dementing disorder, J Alzheimers Dis, 24, 77, 10.3233/JAD-2011-101425

Caldwell, 2015, Targeting the prodromal stage of Alzheimer’s disease: Bioenergetic and mitochondrial opportunities, Neurotherapeutics, 12, 66, 10.1007/s13311-014-0324-8

Yao, 2009, Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease, Proc Natl Acad Sci U S A, 106, 14670, 10.1073/pnas.0903563106

Valla, 2010, Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer’s susceptibility gene, J Alzheimers Dis, 22, 307, 10.3233/JAD-2010-100129

Reddy, 2012, Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: Implications to mitochondria-targeted antioxidant therapeutics, Biochim Biophys Acta, 1822, 639, 10.1016/j.bbadis.2011.10.011

Trushina, 2013, Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer’s disease using metabolomics, PLoS One, 8, e63644, 10.1371/journal.pone.0063644

Jones, 2006, Redefining oxidative stress, Antioxid Redox Signal, 8, 1865, 10.1089/ars.2006.8.1865

Hauptmann, 1996, The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA, Arch Biochem Biophys, 335, 295, 10.1006/abbi.1996.0510

Di Meo, 2016, Role of ROS and RNS sources in physiological and pathological conditions, Oxid Med Cell Longev, 2016, 1245049, 10.1155/2016/1245049

Ray, 2012, Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling, Cell Signal, 24, 981, 10.1016/j.cellsig.2012.01.008

Holmstrom, 2014, Cellular mechanisms and physiological consequences of redox-dependent signalling, Nat Rev Mol Cell Biol, 15, 411, 10.1038/nrm3801

Quinlan, 2013, Sites of reactive oxygen species generation by mitochondria oxidizing different substrates, Redox Biol, 1, 304, 10.1016/j.redox.2013.04.005

Joshi, 2012, The Nrf2-ARE pathway: A valuable therapeutic target for the treatment of neurodegenerative diseases, Recent Pat CNS Drug Discov, 7, 218, 10.2174/157488912803252023

Kensler, 2007, Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway, Annu Rev Pharmacol Toxicol, 47, 89, 10.1146/annurev.pharmtox.46.120604.141046

Denzer, 2016, Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds, Pharmacol Res, 103, 80, 10.1016/j.phrs.2015.11.019

Patel, 2016, Targeting oxidative stress in central nervous system disorders, Trends Pharmacol Sci, 37, 768, 10.1016/j.tips.2016.06.007

Bhat, 2015, Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight, Biomed Pharmacother, 74, 101, 10.1016/j.biopha.2015.07.025

Ramsey, 2007, Expression of Nrf2 in neurodegenerative diseases, J Neuropathol Exp Neurol, 66, 75, 10.1097/nen.0b013e31802d6da9

Tanji, 2013, Keap1 is localized in neuronal and glial cytoplasmic inclusions in various neurodegenerative diseases, J Neuropathol Exp Neurol, 72, 18, 10.1097/NEN.0b013e31827b5713

Schipper, 2006, Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment, Neurobiol Aging, 27, 252, 10.1016/j.neurobiolaging.2005.01.016

Kanninen, 2008, Nuclear factor erythroid 2-related factor 2 protects against beta amyloid, Mol Cell Neurosci, 39, 302, 10.1016/j.mcn.2008.07.010

Kim, 2006, Decreased plasma antioxidants in patients with Alzheimer’s disease, Int J Geriatr Psychiatry, 21, 344, 10.1002/gps.1469

Uttara, 2009, Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options, Curr Neuropharmacol, 7, 65, 10.2174/157015909787602823

Smith, 1995, Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer’s disease, J Neurochem, 64, 2660, 10.1046/j.1471-4159.1995.64062660.x

Butterfield, 2014, Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain, Biochim Biophys Acta, 1842, 1693, 10.1016/j.bbadis.2014.06.010

Kosenko, 2014, Pathogenesis of Alzheimer disease: Role of oxidative stress, amyloid-beta peptides, systemic ammonia and erythrocyte energy metabolism, CNS Neurol Disord Drug Targets, 13, 112, 10.2174/18715273113126660130

Castellani, 2012, The role of iron as a mediator of oxidative stress in Alzheimer disease, Biofactors, 38, 133, 10.1002/biof.1010

Zhu, 2003, Oxidative stress and neuronal adaptation in Alzheimer disease: The role of SAPK pathways, Antioxid Redox Signal, 5, 571, 10.1089/152308603770310220

Markesbery, 1999, The role of oxidative stress in Alzheimer disease, Arch Neurol, 56, 1449, 10.1001/archneur.56.12.1449

Pratico, 2008, Oxidative stress hypothesis in Alzheimer’s disease: A reappraisal, Trends Pharmacol Sci, 29, 609, 10.1016/j.tips.2008.09.001

Schippling, 2000, Increased lipoprotein oxidation in Alzheimer’s disease, Free Radic Biol Med, 28, 351, 10.1016/S0891-5849(99)00247-6

Smith, 1994, Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer’s disease, Am J Pathol, 145, 42

Ramassamy, 2001, Impact of apoE deficiency on oxidative insults and antioxidant levels in the brain, Brain Res Mol Brain Res, 86, 76, 10.1016/S0169-328X(00)00268-0

Picklo, 2002, Carbonyl toxicology and Alzheimer’s disease, Toxicol Appl Pharmacol, 184, 187, 10.1006/taap.2002.9506

Bassett, 2003, Lipoproteins and lipid peroxidation in Alzheimer’s disease, J Nutr Health Aging, 7, 24

Mecocci, 1997, Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain, Mol Chem Neuropathol, 31, 53, 10.1007/BF02815160

Lovell, 2007, Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer’s disease, Nucleic Acids Res, 35, 7497, 10.1093/nar/gkm821

Lovell, 2008, Oxidatively modified RNA in mild cognitive impairment, Neurobiol Dis, 29, 169, 10.1016/j.nbd.2007.07.030

Bradley-Whitman, 2014, Nucleic acid oxidation: An early feature of Alzheimer’s disease, J Neurochem, 128, 294, 10.1111/jnc.12444

Migliore, 2005, Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients, Neurobiol Aging, 26, 567, 10.1016/j.neurobiolaging.2004.07.016

Greenough, 2013, Metal dyshomeostasis and oxidative stress in Alzheimer’s disease, Neurochem Int, 62, 540, 10.1016/j.neuint.2012.08.014

Wang P , Wang ZY (2016) Metal ions influx is a double edged sword for the pathogenesis of Alzheimer’s disease. Ageing Res Rev. doi: 10.1016/j.arr.2016.10.003

Liu, 2006, Metal exposure and Alzheimer’s pathogenesis, J Struct Biol, 155, 45, 10.1016/j.jsb.2005.12.011

Danscher, 1997, Increased amount of zinc in the hippocampus and amygdala of Alzheimer’s diseased brains: A proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material, J Neurosci Methods, 76, 53, 10.1016/S0165-0270(97)00079-4

Friedlich, 2004, Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer’s disease, J Neurosci, 24, 3453, 10.1523/JNEUROSCI.0297-04.2004

Lee, 2002, Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice, Proc Natl Acad Sci U S A, 99, 7705, 10.1073/pnas.092034699

Lee, 1999, Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice, J Neurosci, 19, RC10, 10.1523/JNEUROSCI.19-11-j0002.1999

Lovell, 1998, Copper, iron and zinc in Alzheimer’s disease senile plaques, J Neurol Sci, 158, 47, 10.1016/S0022-510X(98)00092-6

Miller, 2006, Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer’s disease, J Struct Biol, 155, 30, 10.1016/j.jsb.2005.09.004

Stoltenberg, 2007, Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency, Neuroscience, 150, 357, 10.1016/j.neuroscience.2007.09.025

Suh, 2000, Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer’s diseased brains, Brain Res, 852, 274, 10.1016/S0006-8993(99)02096-X

Boom, 2004, Astrocytic calcium/zinc binding protein S100A6 over expression in Alzheimer’s disease and in PS1/APP transgenic mice models, Biochim Biophys Acta, 1742, 161, 10.1016/j.bbamcr.2004.09.011

Heizmann, 1998, New perspectives on S100 proteins: A multi-functional Ca(2+)-, Zn(2+)- and Cu(2+)-binding protein family, Biometals, 11, 383, 10.1023/A:1009212521172

Barnham, 2014, Biological metals and metal-targeting compounds in major neurodegenerative diseases, Chem Soc Rev, 43, 6727, 10.1039/C4CS00138A

Lammich, 1999, Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease, Proc Natl Acad Sci U S A, 96, 3922, 10.1073/pnas.96.7.3922

Bush, 1994, Rapid induction of Alzheimer A beta amyloid formation by zinc, Science, 265, 1464, 10.1126/science.8073293

Tougu, 2008, Binding of zinc(II) and copper(II) to the full-length Alzheimer’s amyloid-beta peptide, J Neurochem, 104, 1249, 10.1111/j.1471-4159.2007.05061.x

Mantyh, 1993, Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide, J Neurochem, 61, 1171, 10.1111/j.1471-4159.1993.tb03639.x

Sayre, 2000, In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s disease: A central role for bound transition metals, J Neurochem, 74, 270, 10.1046/j.1471-4159.2000.0740270.x

Boom, 2009, Bimodal modulation of tau protein phosphorylation and conformation by extracellular Zn2+ in human-tau transfected cells, Biochim Biophys Acta, 1793, 1058, 10.1016/j.bbamcr.2008.11.011

Stohs, 1995, Oxidative mechanisms in the toxicity of metal ions, Free Radic Biol Med, 18, 321, 10.1016/0891-5849(94)00159-H

Huang, 1999, The A beta peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction, Biochemistry, 38, 7609, 10.1021/bi990438f

Adlard, 2008, Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta, Neuron, 59, 43, 10.1016/j.neuron.2008.06.018

Cherny, 2001, Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice, Neuron, 30, 665, 10.1016/S0896-6273(01)00317-8

Opazo, 2003, Copper reduction by copper binding proteins and its relation to neurodegenerative diseases, Biometals, 16, 91, 10.1023/A:1020795422185

Cristovao, 2016, Metals and Neuronal Metal Binding Proteins Implicated in Alzheimer’s Disease, Oxid Med Cell Longev, 2016, 9812178, 10.1155/2016/9812178

Nakajima, 2001, Microglia: Activation and their significance in the central nervous system, J Biochem, 130, 169, 10.1093/oxfordjournals.jbchem.a002969

Gibson, 2008, Oxidant-induced changes in mitochondria and calcium dynamics in the pathophysiology of Alzheimer’s disease, Ann N Y Acad Sci, 1147, 221, 10.1196/annals.1427.038

Manczak, 2006, Mitochondria are a direct site of Abeta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression, Hum Mol Genet, 15, 1437, 10.1093/hmg/ddl066

Mattson, 2005, Alzheimer peptides perturb lipid-regulating enzymes, Nat Cell Biol, 7, 1045, 10.1038/ncb1105-1045

Lee, 2004, Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway, J Cell Biol, 164, 123, 10.1083/jcb.200307017

Grimm, 2005, Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin, Nat Cell Biol, 7, 1118, 10.1038/ncb1313

Cutler, 2004, Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease, Proc Natl Acad Sci U S A, 101, 2070, 10.1073/pnas.0305799101

Chalfant, 1999, Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid, J Biol Chem, 274, 20313, 10.1074/jbc.274.29.20313

Haughey, 2010, Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis, Biochim Biophys Acta, 1801, 878, 10.1016/j.bbalip.2010.05.003

Blass, 1990, Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation, Arch Neurol, 47, 864, 10.1001/archneur.1990.00530080046009

Szabados, 2004, A chronic Alzheimer’s model evoked by mitochondrial poison sodium azide for pharmacological investigations, Behav Brain Res, 154, 31, 10.1016/j.bbr.2004.01.016

Ichimura, 2003, Mechano-oxidative coupling by mitochondria induces proinflammatory responses in lung venular capillaries, J Clin Invest, 111, 691, 10.1172/JCI17271

Colell, 2009, Mitochondria, cholesterol and amyloid beta peptide: A dangerous trio in Alzheimer disease, J Bioenerg Biomembr, 41, 417, 10.1007/s10863-009-9242-6

Rosales-Corral, 2012, Alterations in lipid levels of mitochondrial membranes induced by amyloid-beta: A protective role of melatonin, Int J Alzheimers Dis, 2012, 459806

Mondragon-Rodriguez, 2013, Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: Implications for Alzheimer’s disease, Oxid Med Cell Longev, 2013, 940603, 10.1155/2013/940603

Vlassenko, 2010, Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition, Proc Natl Acad Sci U S A, 107, 17763, 10.1073/pnas.1010461107

Onyango, 2010, Nerve growth factor attenuates oxidant-induced beta-amyloid neurotoxicity in sporadic Alzheimer’s disease cybrids, J Neurochem, 114, 1605, 10.1111/j.1471-4159.2010.06871.x

Khan, 2000, Alzheimer’s disease cybrids replicate beta-amyloid abnormalities through cell death pathways, Ann Neurol, 48, 148, 10.1002/1531-8249(200008)48:2<148::AID-ANA3>3.0.CO;2-7

Gasparini, 1997, Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells, Neurosci Lett, 231, 113, 10.1016/S0304-3940(97)00536-3

Gabuzda, 1994, Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative, J Biol Chem, 269, 13623, 10.1016/S0021-9258(17)36875-8

Webster, 1998, The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells, J Neural Transm (Vienna), 105, 839, 10.1007/s007020050098

Henriques, 2005, Sodium azide and 2-deoxy-D-glucose-induced cellular stress affects phosphorylation-dependent AbetaPP processing, J Alzheimers Dis, 7, 201, 10.3233/JAD-2005-7302

Szule, 2015, The structure and function of ‘active zone material’ at synapses, Philos Trans R Soc Lond B Biol Sci, 370, 1672, 10.1098/rstb.2014.0189

Malenka, 2004, LTP and LTD: An embarrassment of riches, Neuron, 44, 5, 10.1016/j.neuron.2004.09.012

Neves, 2008, Synaptic plasticity, memory and the hippocampus: A neural network approach to causality, Nat Rev Neurosci, 9, 65, 10.1038/nrn2303

Mattson, 2006, Ageing and neuronal vulnerability, Nat Rev Neurosci, 7, 278, 10.1038/nrn1886

Jang, 2016, Emerging link between Alzheimer’s disease and homeostatic synaptic plasticity, Neural Plas, 2016, 7969272

DeKosky, 1990, Synapse loss in frontal cortex biopsies in Alzheimer’s disease: Correlation with cognitive severity, Ann Neurol, 27, 457, 10.1002/ana.410270502

Hamos, 1989, Synaptic loss in Alzheimer’s disease and other dementias, Neurology, 39, 355, 10.1212/WNL.39.3.355

Robinson, 2014, Perforant path synaptic loss correlates with cognitive impairment and Alzheimer’s disease in the oldest-old, Brain, 137, 2578, 10.1093/brain/awu190

Terry, 1991, Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment, Ann Neurol, 30, 572, 10.1002/ana.410300410

Serrano-Pozo, 2011, Neuropathological alterations in Alzheimer disease, Cold Spring Harb Perspect Med, 1, a006189, 10.1101/cshperspect.a006189

Cooper, 2012, The BCM theory of synapse modification at 30: Interaction of theory with experiment, Nat Rev Neurosci, 13, 798, 10.1038/nrn3353

Spires-Jones, 2014, The intersection of amyloid beta and tau at synapses in Alzheimer’s disease, Neuron, 82, 756, 10.1016/j.neuron.2014.05.004

Kamat, 2016, Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer’s disease: Understanding the therapeutics strategies, Mol Neurobiol, 53, 648, 10.1007/s12035-014-9053-6

Reddy, 2008, Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease, Trends Mol Med, 14, 45, 10.1016/j.molmed.2007.12.002

Newcomer, 2000, NMDA receptor function, memory, and brain aging, Dialogues Clin Neurosci, 2, 219, 10.31887/DCNS.2000.2.3/jnewcomer

Frankland, 2005, The organization of recent and remote memories, Nat Rev Neurosci, 6, 119, 10.1038/nrn1607

Snyder, 2005, Regulation of NMDA receptor trafficking by amyloid-beta, Nat Neurosci, 8, 1051, 10.1038/nn1503

Bezprozvanny, 2008, Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease, Trends Neurosci, 31, 454, 10.1016/j.tins.2008.06.005

Parsons, 2014, Extrasynaptic NMDA receptor involvement in central nervous system disorders, Neuron, 82, 279, 10.1016/j.neuron.2014.03.030

Lipton, 2006, Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond, Nat Rev Drug Discov, 5, 160, 10.1038/nrd1958

Hsieh, 2006, AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss, Neuron, 52, 831, 10.1016/j.neuron.2006.10.035

Li, 2016, Implications of GABAergic neurotransmission in Alzheimer’s disease, Front Aging Neurosci, 8, 31, 10.3389/fnagi.2016.00031

Schliebs, 2011, The cholinergic system in aging and neuronal degeneration, Behav Brain Res, 221, 555, 10.1016/j.bbr.2010.11.058

Campos, 2016, Treatment of cognitive deficits in Alzheimer’s disease: A psychopharmacological review, Psychiatr Danub, 28, 2

Ellis, 2015, Metabolic modifications in human biofluids suggest the involvement of sphingolipid, antioxidant, and glutamate metabolism in Alzheimer’s disease pathogenesis, J Alzheimers Dis, 46, 313, 10.3233/JAD-141899

Trushina, 2013, Recent advances in the application of metabolomics to Alzheimer’s Disease, Biochim Biophys Acta, 1842, 1232, 10.1016/j.bbadis.2013.06.014

De Felice, 2007, Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine, J Biol Chem, 282, 11590, 10.1074/jbc.M607483200

Rai, 2013, A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats, J Neuroimmunol, 254, 1, 10.1016/j.jneuroim.2012.08.008

Kamat, 2013, Okadaic acid-induced Tau phosphorylation in rat brain: Role of NMDA recetor, Neuroscience, 238, 97, 10.1016/j.neuroscience.2013.01.075

Morris, 2016, The deleterious effects of oxidative and nitrosative stress on palmitoylation, membrane lipid rafts and lipid-based cellular signalling: New drug targets in neuroimmune disorders, Mol Neurobiol, 53, 4638, 10.1007/s12035-015-9392-y

Han, 2010, Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer’s disease, Biochim Biophys Acta, 1801, 774, 10.1016/j.bbalip.2010.01.010

Han, 2011, Metabolomics in early Alzheimer’s disease: Identification of altered plasma sphingolipidome using shotgun lipidomics, PLoS One, 6, e21643, 10.1371/journal.pone.0021643

Schneider, 2009, Current Alzheimer’s disease clinical trials: Methods and placebo outcomes, Alzheimers Dement, 5, 388, 10.1016/j.jalz.2009.07.038

Cummings, 2016, Drug development in Alzheimer’s disease: The path to 2025, Alzheimers Res Ther, 8, 39, 10.1186/s13195-016-0207-9

Padurariu, 2013, The oxidative stress hypothesis in Alzheimer’s disease, Psychiatr Danub, 25, 401

Sancheti, 2014, Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer’s disease: A 13C NMR study, J Cereb Blood Flow Metab, 34, 288, 10.1038/jcbfm.2013.196

Quinn, 2007, Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice, Neurobiol Aging, 28, 213, 10.1016/j.neurobiolaging.2005.12.014

Rajasekar, 2013, Neuroprotective effect of curcumin on okadaic acid induced memory impairment in mice, Eur J Pharmacol, 715, 381, 10.1016/j.ejphar.2013.04.033

Zhou, 2016, An overview on therapeutics attenuating amyloid beta level in Alzheimer’s disease: Targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels, Am J Transl Res, 8, 246

Kang, 2006, A randomized trial of vitamin E supplementation and cognitive function in women, Arch Intern Med, 166, 2462, 10.1001/archinte.166.22.2462

Kang, 2009, Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women’s Antioxidant and Cardiovascular Study, Circulation, 119, 2772, 10.1161/CIRCULATIONAHA.108.816900

Petersen, 2005, Vitamin E and donepezil for the treatment of mild cognitive impairment, N Engl J Med, 352, 2379, 10.1056/NEJMoa050151

Sano, 1997, A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study, N Engl J Med, 336, 1216, 10.1056/NEJM199704243361704

Dysken, 2014, Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial, JAMA, 311, 33, 10.1001/jama.2013.282834

Miller, 2005, Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality, Ann Intern Med, 142, 37, 10.7326/0003-4819-142-1-200501040-00110

Arlt, 2012, Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer’s disease, Neurochem Res, 37, 2706, 10.1007/s11064-012-0860-8

Galasko, 2012, Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures, Arch Neurol, 69, 836, 10.1001/archneurol.2012.85

Ringman, 2012, Oral curcumin for Alzheimer’s disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study, Alzheimers Res Ther, 4, 43, 10.1186/alzrt146

Wojtunik-Kulesza, 2016, The influence of common free radicals and antioxidants on development of Alzheimer’s Disease, Biomed Pharmacother, 78, 39, 10.1016/j.biopha.2015.12.024

Mecocci, 2012, Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease, Biochim Biophys Acta, 1822, 631, 10.1016/j.bbadis.2011.10.006

Tolonen, 1985, Vitamin E and selenium supplementation in geriatric patients: A double-blind preliminary clinical trial, Biol Trace Elem Res, 7, 161, 10.1007/BF02916538

Kryscio, 2013, A randomized controlled Alzheimer’s disease prevention trial’s evolution into an exposure trial: The PREADViSE Trial, J Nutr Health Aging, 17, 72, 10.1007/s12603-013-0004-0

Dias, 2014, Multi-target directed drugs: A modern approach for design of new drugs for the treatment of Alzheimer’s disease, Curr Neuropharmacol, 12, 239, 10.2174/1570159X1203140511153200

Remington, 2016, Maintenance of cognitive performance and mood for individuals with Alzheimer’s disease following consumption of a nutraceutical formulation: A one-year, open-label study, J Alzheimers Dis, 51, 991, 10.3233/JAD-151098

Chan, 2010, A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia, J Nutr Health Aging, 14, 224, 10.1007/s12603-010-0054-5

Banerjee, 2011, A double-blind randomized placebo-controlled clinical study to evaluate the efficacy and safety of a polyherbal formulation in geriatric age group: A phase IV clinical report, J Ethnopharmacol, 134, 429, 10.1016/j.jep.2010.12.044

Meng, 2002, Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo, Mol Cell, 9, 387, 10.1016/S1097-2765(02)00445-8

Kwon, 2004, Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors, Proc Natl Acad Sci U S A, 101, 16419, 10.1073/pnas.0407396101

Edgar, 2012, Peroxiredoxins are conserved markers of circadian rhythms, Nature, 485, 459, 10.1038/nature11088

Ha, 2005, A direct role for dual oxidase in Drosophila gut immunity, Science, 310, 847, 10.1126/science.1117311

Mathers, 2004, Antioxidant and cytoprotective responses to redox stress, Biochem Soc Symp, 157

Mattson, 2008, Hormesis defined, Ageing Res Rev, 7, 1, 10.1016/j.arr.2007.08.007

Ristow, 2014, Unraveling the truth about antioxidants: Mitohormesis explains ROS-induced health benefits, Nat Med, 20, 709, 10.1038/nm.3624

Schmeisser, 2013, Neuronal ROS signaling rather than AMPK/sirtuin-mediated energy sensing links dietary restriction to lifespan extension, Mol Metab, 2, 92, 10.1016/j.molmet.2013.02.002

Droge, 2002, Free radicals in the physiological control of cell function, Physiol Rev, 82, 47, 10.1152/physrev.00018.2001

Kumar, 2015, A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions, Front Pharmaco, 6, 206

Feniouk BA , Skulachev VP (2016) Cellular and molecular mechanisms of action of mitochondria-targeted antioxidants. Curr Aging Sci 9, doi: 10.2174-1874609809666160921113706

Pospisilik, 2007, Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes, Cell, 131, 476, 10.1016/j.cell.2007.08.047

Wredenberg, 2006, Respiratory chain dysfunction in skeletal muscle does not cause insulin resistance, Biochem Biophys Res Commun, 350, 202, 10.1016/j.bbrc.2006.09.029

Vernochet, 2012, Adipose-specific deletion of TFAM increases mitochondrial oxidation and protects mice against obesity and insulin resistance, Cell Metab, 16, 765, 10.1016/j.cmet.2012.10.016

Quintens, 2013, Mice deficient in the respiratory chain gene Cox6a2 are protected against high-fat diet-induced obesity and insulin resistance, PLoS One, 8, e56719, 10.1371/journal.pone.0056719

Raule, 2014, The co-occurrence of mtDNA mutations on different oxidative phosphorylation subunits, not detected by haplogroup analysis, affects human longevity and is population specific, Aging Cell, 13, 401, 10.1111/acel.12186

Copeland, 2009, Extension of Drosophila life span by RNAi of the mitochondrial respiratory chain, Curr Biol, 19, 1591, 10.1016/j.cub.2009.08.016

Lee, 2003, A systematic RNAi screen identifies a critical role for mitochondria in C. elegans longevity, Nat Genet, 33, 40, 10.1038/ng1056

Liu, 2005, Evolutionary conservation of the clk-1-dependent mechanism of longevity: Loss of mclk1 increases cellular fitness and lifespan in mice, Genes Dev, 19, 2424, 10.1101/gad.1352905

Zhang, 2015, Modulation of mitochondrial complex I activity averts cognitive decline in multiple animal models of familial Alzheimer’s disease, E Bio Medicine, 2, 294

Baumgart, 2016, Longitudinal RNA-Seq analysis of vertebrate aging identifies mitochondrial complex i as a small-molecule-sensitive modifier of lifespan, Cell Syst, 2, 122, 10.1016/j.cels.2016.01.014

Mendiola-Precoma, 2016, Therapies for prevention and treatment of Alzheimer’s disease, Biomed Res Int, 2016, 2589276, 10.1155/2016/2589276

Baumgart, 2015, Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective, Alzheimers Dement, 11, 718, 10.1016/j.jalz.2015.05.016

Bertram, 2016, Exercise for the diabetic brain: Howhysical training may help prevent dementia and Alzheimer’s disease in T2DM patients, Endocrine, 53, 350, 10.1007/s12020-016-0976-8

Baker, 2010, Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer’s disease, J Alzheimers Dis, 22, 569, 10.3233/JAD-2010-100768

Merry, 2016, Mitohormesis in exercise training, Free Radic Biol Med, 98, 123, 10.1016/j.freeradbiomed.2015.11.032

Ntsapi, 2016, Caloric restriction and the precision-control of autophagy: A strategy for delaying neurodegenerative disease progression, Exp Gerontol, 83, 97, 10.1016/j.exger.2016.07.014

Van Cauwenberghe, 2016, Caloric restriction: Beneficial effects on brain aging and Alzheimer’s disease, Mamm Genome, 27, 300, 10.1007/s00335-016-9647-6

Hanson, 2015, Differential effects of meal challenges on cognition, metabolism, and biomarkers for apolipoprotein E ɛ4 carriers and adults with mild cognitive impairment, J Alzheimers Dis, 48, 205, 10.3233/JAD-150273

Zhang, 2016, Altered brain energetics induces mitochondrial fission arrest in Alzheimer’s Disease, Sci Rep, 6, 18725, 10.1038/srep18725